EP Patent

EP1551842A1 — Pyradazine compounds as gsk-3 inhibitors

Assigned to SmithKline Beecham Corp · Expires 2005-07-13 · 21y expired

What this patent protects

The present invention relates generally to inhibitors of the kinases, such as GSK3, and more particularly to fused pyradazine compounds according to formula (I) and methods of their use.

USPTO Abstract

The present invention relates generally to inhibitors of the kinases, such as GSK3, and more particularly to fused pyradazine compounds according to formula (I) and methods of their use.

Drugs covered by this patent

Patent Metadata

Patent number
EP1551842A1
Jurisdiction
EP
Classification
—
Expires
2005-07-13
Drug substance claim
No
Drug product claim
No
Assignee
SmithKline Beecham Corp
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.